prazosin ๐Ÿถ Veterinary Use | Indications/Contra | FAERs-F | FAERs-M | Orange Bk | BioActivity |

Stem definitionDrug idCAS RN
antihypertensive substances, prazosin derivatives 4209 19216-56-9

Description:

MoleculeDescription

Molfile Inchi Smiles

Synonyms:

  • prazosin
  • prazosin hydrochloride
  • furazosin
  • prazosin HCl
A selective adrenergic alpha-1 antagonist used in the treatment of HEART FAILURE; HYPERTENSION; PHEOCHROMOCYTOMA; RAYNAUD DISEASE; PROSTATIC HYPERTROPHY; and URINARY RETENTION.
  • Molecular weight: 383.41
  • Formula: C19H21N5O4
  • CLOGP: 2.08
  • LIPINSKI: 0
  • HAC: 9
  • HDO: 1
  • TPSA: 106.95
  • ALOGS: -2.74
  • ROTB: 4

  • Status: OFP

  • Legend:
    OFP - off patent
    OFM - off market
    ONP - on patent

Drug dosage:

DoseUnitRoute
5 mg O

ADMET properties:

PropertyValueReference
BDDCS (Biopharmaceutical Drug Disposition Classification System) 1 Benet LZ, Broccatelli F, Oprea TI
S (Water solubility) 1.40 mg/mL Benet LZ, Broccatelli F, Oprea TI
EoM (Fraction excreted unchanged in urine) 0.50 % Benet LZ, Broccatelli F, Oprea TI
MRTD (Maximum Recommended Therapeutic Daily Dose) 1.49 ยตM/kg/day Contrera JF, Matthews EJ, Kruhlak NL, Benz RD
BA (Bioavailability) 68 % Kim MT, Sedykh A, Chakravarti SK, Saiakhov RD, Zhu H
Vd (Volume of distribution) 0.73 L/kg Lombardo F, Berellini G, Obach RS
CL (Clearance) 4.70 mL/min/kg Lombardo F, Berellini G, Obach RS
fu (Fraction unbound in plasma) 0.06 % Lombardo F, Berellini G, Obach RS
t_half (Half-life) 2 hours Lombardo F, Berellini G, Obach RS

Approvals:

DateAgencyCompanyOrphan
June 23, 1976 FDA PFIZER

FDA Adverse Event Reporting System (Female)

MedDRA adverse event termLikelihood ratioLikelihood ratio thresholdPatients taking drug having adverse eventPatients taking drug not having adverse eventPatients not taking drug having adverse eventPatients not taking drug not having adverse event
Atrioventricular block first degree 108.13 16.06 37 6505 7236 63475244
Completed suicide 74.30 16.06 83 6459 145590 63336890
Suicidal ideation 53.04 16.06 47 6495 62374 63420106
Toxicity to various agents 51.95 16.06 92 6450 247158 63235322
Unmasking of previously unidentified disease 50.32 16.06 13 6529 963 63481517
Electrocardiogram ST segment elevation 43.26 16.06 16 6526 3911 63478569
Electrocardiogram repolarisation abnormality 41.93 16.06 12 6530 1305 63481175
Sinus bradycardia 41.34 16.06 23 6519 14528 63467952
Norepinephrine increased 41.26 16.06 7 6535 62 63482418
Circulatory collapse 39.81 16.06 26 6516 21912 63460568
Systolic dysfunction 39.63 16.06 12 6530 1587 63480893
Posterior reversible encephalopathy syndrome 37.58 16.06 23 6519 17322 63465158
Cardiac arrest 34.45 16.06 45 6497 92500 63389980
Electrocardiogram QRS complex prolonged 33.62 16.06 15 6527 5923 63476557
Cardio-respiratory arrest 31.94 16.06 35 6507 59924 63422556
Sinus tachycardia 30.57 16.06 23 6519 24245 63458235
Ventricular hypokinesia 30.42 16.06 13 6529 4631 63477849
Drug withdrawal syndrome 28.25 16.06 23 6519 27171 63455309
Hypotension 26.92 16.06 75 6467 272529 63209951
Depression 26.65 16.06 61 6481 196431 63286049
Cardiac hypertrophy 26.58 16.06 8 6534 1037 63481443
Suspected suicide 26.11 16.06 13 6529 6555 63475925
Intentional overdose 25.96 16.06 35 6507 74117 63408363
Hypertrichosis 25.79 16.06 8 6534 1146 63481334
Cardiotoxicity 25.79 16.06 14 6528 8424 63474056
Post-traumatic stress disorder 25.74 16.06 12 6530 5239 63477241
Overdose 25.63 16.06 44 6498 115034 63367446
Metabolic acidosis 23.47 16.06 26 6516 45043 63437437
Withdrawal syndrome 23.09 16.06 18 6524 19979 63462501
Phaeochromocytoma 22.38 16.06 6 6536 513 63481967
Electrocardiogram QT prolonged 22.22 16.06 29 6513 59501 63422979
Ventricular extrasystoles 21.56 16.06 14 6528 11673 63470807
Myasthenic syndrome 21.17 16.06 5 6537 255 63482225
Renal papillary necrosis 20.88 16.06 5 6537 271 63482209
Status epilepticus 20.44 16.06 15 6527 15218 63467262
Dissociative identity disorder 20.41 16.06 4 6538 83 63482397
Blood prolactin increased 20.31 16.06 9 6533 3494 63478986
Antipsychotic drug level decreased 19.66 16.06 5 6537 348 63482132
Drug intolerance 19.57 16.06 4 6538 308657 63173823
Anxiety 18.71 16.06 57 6485 217484 63264996
Alcoholism 18.54 16.06 7 6535 1811 63480669
Electrocardiogram QRS complex shortened 18.25 16.06 5 6537 464 63482016
Occipital neuralgia 18.08 16.06 5 6537 480 63482000
Haemophagocytic lymphohistiocytosis 17.83 16.06 12 6530 10615 63471865
Joint swelling 17.46 16.06 6 6536 327660 63154820
Coma scale abnormal 17.01 16.06 9 6533 5144 63477336
Hypertensive encephalopathy 16.73 16.06 5 6537 633 63481847
Activation syndrome 16.68 16.06 4 6538 218 63482262
Stress cardiomyopathy 16.65 16.06 11 6531 9439 63473041
Thyroxine free decreased 16.28 16.06 5 6537 693 63481787
Cardiogenic shock 16.21 16.06 14 6528 17918 63464562

FDA Adverse Event Reporting System (Male)

MedDRA adverse event termLikelihood ratioLikelihood ratio thresholdPatients taking drug having adverse eventPatients taking drug not having adverse eventPatients not taking drug having adverse eventPatients not taking drug not having adverse event
Antidepressant drug level above therapeutic 107.26 17.20 20 4898 226 34951787
Analgesic drug level above therapeutic 102.46 17.20 20 4898 293 34951720
Parasomnia 74.33 17.20 16 4902 388 34951625
Priapism 65.06 17.20 25 4893 4969 34947044
Sudden cardiac death 53.53 17.20 20 4898 3681 34948332
Serotonin syndrome 51.25 17.20 33 4885 19900 34932113
Abnormal sleep-related event 50.07 17.20 12 4906 475 34951538
Suicidal behaviour 49.22 17.20 15 4903 1482 34950531
Vasoplegia syndrome 38.08 17.20 13 4905 1843 34950170
Drug interaction 35.80 17.20 90 4828 225856 34726157
Suicidal ideation 34.40 17.20 35 4883 40353 34911660
Blood pressure ambulatory increased 32.84 17.20 6 4912 60 34951953
Cardiac autonomic neuropathy 32.57 17.20 6 4912 63 34951950
Somnambulism 31.70 17.20 13 4905 3059 34948954
Pulmonary congestion 31.03 17.20 21 4897 13744 34938269
Tri-iodothyronine decreased 28.97 17.20 6 4912 120 34951893
Non-high-density lipoprotein cholesterol increased 28.25 17.20 6 4912 136 34951877
Supine hypertension 27.58 17.20 7 4911 352 34951661
Lactic acidosis 27.56 17.20 29 4889 34743 34917270
Globulins increased 26.83 17.20 7 4911 393 34951620
Thyroxine decreased 25.66 17.20 6 4912 213 34951800
Compartment syndrome 25.24 17.20 11 4907 3007 34949006
Sinus bradycardia 25.06 17.20 18 4900 12945 34939068
Sleep disorder 24.35 17.20 26 4892 31662 34920351
Spleen tuberculosis 23.99 17.20 4 4914 22 34951991
Electrocardiogram QT prolonged 23.68 17.20 29 4889 40923 34911090
Rhabdomyolysis 22.63 17.20 37 4881 68126 34883887
Overdose 21.97 17.20 43 4875 91016 34860997
Left atrial dilatation 19.08 17.20 8 4910 1988 34950025
Hyperlactacidaemia 18.92 17.20 9 4909 3007 34949006
Troponin T increased 17.76 17.20 8 4910 2363 34949650

FDA Adverse Event Reporting System (Geriatric)

MedDRA adverse event termLikelihood ratioLikelihood ratio thresholdPatients taking drug having adverse eventPatients taking drug not having adverse eventPatients not taking drug having adverse eventPatients not taking drug not having adverse event
Analgesic drug level above therapeutic 96.13 14.11 20 9830 469 79734069
Antidepressant drug level above therapeutic 89.68 14.11 20 9830 656 79733882
Atrioventricular block first degree 88.58 14.11 39 9811 12452 79722086
Completed suicide 78.49 14.11 122 9728 245645 79488893
Parasomnia 76.63 14.11 17 9833 544 79733994
Priapism 70.71 14.11 25 9825 4480 79730058
Sinus bradycardia 67.82 14.11 41 9809 25206 79709332
Sudden cardiac death 49.34 14.11 20 9830 5205 79729333
Posterior reversible encephalopathy syndrome 49.16 14.11 34 9816 26247 79708291
Electrocardiogram QT prolonged 48.84 14.11 58 9792 90328 79644210
Overdose 44.78 14.11 81 9769 184125 79550413
Systolic dysfunction 44.53 14.11 17 9833 3778 79730760
Abnormal sleep-related event 44.44 14.11 12 9838 877 79733661
Hypotension 43.38 14.11 136 9714 440181 79294357
Suicidal ideation 42.92 14.11 50 9800 76290 79658248
Drug interaction 42.52 14.11 130 9720 415053 79319485
Suicidal behaviour 39.74 14.11 15 9835 3232 79731306
Suspected suicide 38.65 14.11 21 9829 10555 79723983
Unmasking of previously unidentified disease 38.42 14.11 13 9837 2044 79732494
Norepinephrine increased 37.98 14.11 7 9843 85 79734453
Toxicity to various agents 35.93 14.11 124 9726 421416 79313122
Electrocardiogram repolarisation abnormality 33.38 14.11 12 9838 2255 79732283
Cardiac autonomic neuropathy 33.27 14.11 6 9844 64 79734474
Blood pressure ambulatory increased 33.27 14.11 6 9844 64 79734474
Serotonin syndrome 33.16 14.11 34 9816 44993 79689545
Electrocardiogram ST segment elevation 31.59 14.11 17 9833 8380 79726158
Lactic acidosis 31.35 14.11 41 9809 70318 79664220
Vasoplegia syndrome 31.23 14.11 13 9837 3617 79730921
Pulmonary congestion 28.64 14.11 25 9825 27075 79707463
Somnambulism 28.52 14.11 14 9836 5707 79728831
Supine hypertension 27.32 14.11 7 9843 417 79734121
Cardiac hypertrophy 25.41 14.11 9 9841 1621 79732917
Ventricular hypokinesia 24.73 14.11 15 9835 9264 79725274
Alcoholism 24.39 14.11 11 9839 3712 79730826
Cardio-respiratory arrest 24.18 14.11 46 9804 108464 79626074
Compartment syndrome 24.04 14.11 12 9838 5070 79729468
Antipsychotic drug level decreased 23.90 14.11 8 9842 1216 79733322
Sinus tachycardia 23.85 14.11 26 9824 36882 79697656
Cardiac arrest 23.59 14.11 60 9790 172036 79562502
Hypertrichosis 23.54 14.11 8 9842 1274 79733264
Circulatory collapse 23.41 14.11 26 9824 37642 79696896
Drug withdrawal syndrome 23.38 14.11 25 9825 34693 79699845
Spleen tuberculosis 23.10 14.11 4 9846 33 79734505
Joint swelling 22.95 14.11 4 9846 288642 79445896
Electrocardiogram QRS complex prolonged 22.60 14.11 15 9835 10818 79723720
Withdrawal syndrome 21.09 14.11 21 9829 26833 79707705
Tardive dyskinesia 20.53 14.11 14 9836 10557 79723981
Drug intolerance 20.27 14.11 4 9846 264115 79470423
Akathisia 19.87 14.11 15 9835 13244 79721294
Tri-iodothyronine decreased 19.53 14.11 5 9845 297 79734241
Non-high-density lipoprotein cholesterol increased 18.93 14.11 5 9845 336 79734202
Cardiotoxicity 18.68 14.11 14 9836 12225 79722313
Rhabdomyolysis 18.55 14.11 40 9810 103091 79631447
Myasthenic syndrome 18.44 14.11 6 9844 836 79733702
Aspiration 18.16 14.11 17 9833 20141 79714397
Syncope 18.13 14.11 56 9794 179393 79555145
Renal papillary necrosis 17.78 14.11 5 9845 425 79734113
Occipital neuralgia 17.28 14.11 5 9845 471 79734067
Muscular dystrophy 16.93 14.11 4 9846 170 79734368
Cardiogenic shock 16.49 14.11 23 9827 41891 79692647
Acute kidney injury 16.40 14.11 115 9735 519289 79215249
Bradycardia 16.27 14.11 45 9805 135512 79599026
Phaeochromocytoma 15.61 14.11 5 9845 662 79733876
Neuroleptic malignant syndrome 15.39 14.11 18 9832 27541 79706997
Electrocardiogram QRS complex shortened 15.17 14.11 5 9845 725 79733813
Globulins increased 15.14 14.11 5 9845 730 79733808
Activation syndrome 14.97 14.11 4 9846 281 79734257
Alopecia 14.89 14.11 5 9845 231350 79503188
Hyperlactacidaemia 14.80 14.11 9 9841 5586 79728952
Pneumonia salmonella 14.78 14.11 3 9847 62 79734476
Blood prolactin increased 14.75 14.11 8 9842 4003 79730535
Ventricular extrasystoles 14.72 14.11 15 9835 19689 79714849
Feeling abnormal 14.54 14.11 48 9802 159151 79575387
Food interaction 14.32 14.11 6 9844 1696 79732842
Thyroxine decreased 14.29 14.11 5 9845 868 79733670
Fall 14.25 14.11 106 9744 487523 79247015

FDA Adverse Event Reporting System (Pediatric)

None

Pharmacologic Action:

SourceCodeDescription
ATC C02CA01 CARDIOVASCULAR SYSTEM
ANTIHYPERTENSIVES
ANTIADRENERGIC AGENTS, PERIPHERALLY ACTING
Alpha-adrenoreceptor antagonists
ATC C02LE01 CARDIOVASCULAR SYSTEM
ANTIHYPERTENSIVES
ANTIHYPERTENSIVES AND DIURETICS IN COMBINATION
Alpha-adrenoreceptor antagonists and diuretics
FDA MoA N0000000099 Adrenergic alpha-Antagonists
FDA EPC N0000175553 alpha-Adrenergic Blocker
MeSH PA D018663 Adrenergic Agents
MeSH PA D058668 Adrenergic alpha-1 Receptor Antagonists
MeSH PA D000317 Adrenergic alpha-Antagonists
MeSH PA D018674 Adrenergic Antagonists
MeSH PA D000959 Antihypertensive Agents
MeSH PA D002317 Cardiovascular Agents
MeSH PA D018377 Neurotransmitter Agents
CHEBI has role CHEBI:35674 antihypertensive drugs
CHEBI has role CHEBI:37890 alpha-adrenergic receptor blockaders
CHEBI has role CHEBI:76779 post-proline endopeptidase inhibitors

Drug Use | Suggest Off label Use Form| |View source of the data|

DiseaseRelationSNOMED_IDDOID
Hypertensive disorder indication 38341003 DOID:10763
Benign prostatic hyperplasia off-label use 266569009
PTSD related nightmares off-label use 428687006
Chronic Post Traumatic Stress Disorder with Trauma-related Nightmares off-label use
End stage renal disease contraindication 46177005 DOID:784
Narcolepsy contraindication 60380001 DOID:8986
Cataract surgery contraindication 110473004
Micturition syncope contraindication 234168001
Syncope contraindication 271594007
Intraoperative floppy iris syndrome contraindication 418801006




๐Ÿถ Veterinary Drug Use

None

๐Ÿถ Veterinary products

None

Acid dissociation constants calculated using MoKa v3.0.0

Dissociation levelDissociation constantType (acidic/basic)
pKa1 7.22 Basic
pKa2 0.72 Basic

Orange Book patent data (new drug applications)

None

Orange Book exclusivity data (new drug applications)

None

Bioactivity Summary:

TargetClassPharosUniProtActionTypeActivity value
(-log[M])
Mechanism
action
Bioact sourceMoA source
Alpha-1D adrenergic receptor GPCR INVERSE AGONIST Ki 9.70 CHEMBL IUPHAR
Alpha-1B adrenergic receptor GPCR INVERSE AGONIST Ki 9.68 CHEMBL IUPHAR
Alpha-1A adrenergic receptor GPCR INVERSE AGONIST Ki 10.40 CHEMBL IUPHAR
5-hydroxytryptamine receptor 2B GPCR Ki 5.58 DRUG MATRIX
Alpha-2B adrenergic receptor GPCR Ki 7.89 CHEMBL
5-hydroxytryptamine receptor 1D GPCR Ki 9.48 CHEMBL
Alpha-2C adrenergic receptor GPCR Ki 7.62 CHEMBL
Adenosine receptor A3 GPCR IC50 9.07 CHEMBL
D(4) dopamine receptor GPCR Ki 5.08 CHEMBL
Ribosyldihydronicotinamide dehydrogenase [quinone] Enzyme IC50 8.11 CHEMBL
Matrix metalloproteinase-9 Enzyme IC50 5.16 DRUG MATRIX
Interstitial collagenase Enzyme IC50 5.39 DRUG MATRIX
Solute carrier family 22 member 1 Transporter IC50 5 CHEMBL
Solute carrier family 22 member 2 Transporter IC50 4.87 CHEMBL
Multidrug and toxin extrusion protein 1 Transporter IC50 5.80 CHEMBL
Multidrug and toxin extrusion protein 2 Transporter IC50 4.42 CHEMBL
Sodium channel alpha subunits; brain (Types I, II, III) Ion channel IC50 5 CHEMBL
Alpha-2A adrenergic receptor GPCR Ki 6.68 CHEMBL
Potassium voltage-gated channel subfamily H member 2 Ion channel IC50 5.80 CHEMBL
5-hydroxytryptamine receptor 2A GPCR Ki 7.73 WOMBAT-PK
Alpha-1B adrenergic receptor GPCR Ki 10 CHEMBL
Alpha-1A adrenergic receptor GPCR Ki 10.15 CHEMBL
Alpha-1D adrenergic receptor GPCR Ki 9.70 CHEMBL
Mu-type opioid receptor GPCR Ki 9.70 CHEMBL
D(2) dopamine receptor GPCR IC50 4.96 CHEMBL
5-hydroxytryptamine receptor 1A GPCR Ki 5.63 CHEMBL
5-hydroxytryptamine receptor 2A GPCR Ki 5.82 CHEMBL
Alpha-2A adrenergic receptor GPCR Ki 5.78 CHEMBL
Alpha-1A adrenergic receptor GPCR Ki 9.77 CHEMBL
Alpha-2A adrenergic receptor GPCR Ki 5.39 CHEMBL
Alpha-2A adrenergic receptor GPCR Ki 6.97 CHEMBL
Alpha-1B adrenergic receptor GPCR Ki 9.08 CHEMBL
Adrenergic receptor alpha-2 GPCR Ki 9.40 CHEMBL
Adrenergic receptor alpha-1 GPCR Kd 10.99 CHEMBL
Serotonin 2 (5-HT2) receptor GPCR IC50 4.38 CHEMBL
Alpha-2 adrenergic receptor GPCR Ki 7.89 CHEMBL
Beta-casein Unclassified Ki 9.44 CHEMBL

External reference:

IDSource
4019901 VUID
N0000147986 NUI
D00609 KEGG_DRUG
19237-84-4 SECONDARY_CAS_RN
4018850 VANDF
4019901 VANDF
C0032912 UMLSCUI
CHEBI:8364 CHEBI
XRA PDB_CHEM_ID
CHEMBL2 ChEMBL_ID
CHEMBL1558 ChEMBL_ID
D011224 MESH_DESCRIPTOR_UI
DB00457 DRUGBANK_ID
503 IUPHAR_LIGAND_ID
2593 INN_ID
XM03YJ541D UNII
4893 PUBCHEM_CID
203210 RXNORM
2426 MMSL
5345 MMSL
d00138 MMSL
000635 NDDF
004491 NDDF
387283005 SNOMEDCT_US
387433003 SNOMEDCT_US
76058001 SNOMEDCT_US

Pharmaceutical products:

ProductCategoryIngredientsNDCFormQuantityRouteMarketingLabel
Minipress HUMAN PRESCRIPTION DRUG LABEL 1 0069-4310 CAPSULE 1 mg ORAL NDA 22 sections
Minipress HUMAN PRESCRIPTION DRUG LABEL 1 0069-4370 CAPSULE 2 mg ORAL NDA 22 sections
Minipress HUMAN PRESCRIPTION DRUG LABEL 1 0069-4380 CAPSULE 5 mg ORAL NDA 22 sections
Prazosin Hydrochloride HUMAN PRESCRIPTION DRUG LABEL 1 0093-4067 CAPSULE 1 mg ORAL ANDA 21 sections
Prazosin Hydrochloride HUMAN PRESCRIPTION DRUG LABEL 1 0093-4068 CAPSULE 2 mg ORAL ANDA 21 sections
Prazosin Hydrochloride HUMAN PRESCRIPTION DRUG LABEL 1 0093-4069 CAPSULE 5 mg ORAL ANDA 21 sections
Prazosin Hydrochloride HUMAN PRESCRIPTION DRUG LABEL 1 0378-1101 CAPSULE 1 mg ORAL ANDA 22 sections
Prazosin Hydrochloride HUMAN PRESCRIPTION DRUG LABEL 1 0378-1101 CAPSULE 1 mg ORAL ANDA 22 sections
Prazosin Hydrochloride HUMAN PRESCRIPTION DRUG LABEL 1 0378-1101 CAPSULE 1 mg ORAL ANDA 22 sections
Prazosin Hydrochloride HUMAN PRESCRIPTION DRUG LABEL 1 0378-2302 CAPSULE 2 mg ORAL ANDA 22 sections
Prazosin Hydrochloride HUMAN PRESCRIPTION DRUG LABEL 1 0378-2302 CAPSULE 2 mg ORAL ANDA 22 sections
Prazosin Hydrochloride HUMAN PRESCRIPTION DRUG LABEL 1 0378-2302 CAPSULE 2 mg ORAL ANDA 22 sections
Prazosin Hydrochloride HUMAN PRESCRIPTION DRUG LABEL 1 0378-3205 CAPSULE 5 mg ORAL ANDA 22 sections
Prazosin Hydrochloride HUMAN PRESCRIPTION DRUG LABEL 1 0378-3205 CAPSULE 5 mg ORAL ANDA 22 sections
Prazosin Hydrochloride HUMAN PRESCRIPTION DRUG LABEL 1 0378-3205 CAPSULE 5 mg ORAL ANDA 22 sections
Prazosin Hydrochloride HUMAN PRESCRIPTION DRUG LABEL 1 0904-7020 CAPSULE 1 mg ORAL ANDA 20 sections
Prazosin Hydrochloride HUMAN PRESCRIPTION DRUG LABEL 1 0904-7020 CAPSULE 1 mg ORAL ANDA 20 sections
Prazosin Hydrochloride HUMAN PRESCRIPTION DRUG LABEL 1 0904-7021 CAPSULE 2 mg ORAL ANDA 20 sections
Prazosin Hydrochloride HUMAN PRESCRIPTION DRUG LABEL 1 0904-7021 CAPSULE 2 mg ORAL ANDA 20 sections
Prazosin Hydrochloride HUMAN PRESCRIPTION DRUG LABEL 1 0904-7022 CAPSULE 5 mg ORAL ANDA 20 sections
Prazosin Hydrochloride HUMAN PRESCRIPTION DRUG LABEL 1 0904-7022 CAPSULE 5 mg ORAL ANDA 20 sections
Prazosin Hydrochloride HUMAN PRESCRIPTION DRUG LABEL 1 10135-666 CAPSULE 1 mg ORAL ANDA 21 sections
Prazosin Hydrochloride HUMAN PRESCRIPTION DRUG LABEL 1 10135-666 CAPSULE 1 mg ORAL ANDA 21 sections
Prazosin Hydrochloride HUMAN PRESCRIPTION DRUG LABEL 1 10135-667 CAPSULE 2 mg ORAL ANDA 21 sections
Prazosin Hydrochloride HUMAN PRESCRIPTION DRUG LABEL 1 10135-667 CAPSULE 2 mg ORAL ANDA 21 sections
Prazosin Hydrochloride HUMAN PRESCRIPTION DRUG LABEL 1 10135-668 CAPSULE 5 mg ORAL ANDA 21 sections
Prazosin Hydrochloride HUMAN PRESCRIPTION DRUG LABEL 1 10135-668 CAPSULE 5 mg ORAL ANDA 21 sections
Prazosin Hydrochloride HUMAN PRESCRIPTION DRUG LABEL 1 33261-860 CAPSULE 1 mg ORAL ANDA 21 sections
Prazosin Hydrochloride HUMAN PRESCRIPTION DRUG LABEL 1 33261-861 CAPSULE 2 mg ORAL ANDA 21 sections
Prazosin Hydrochloride HUMAN PRESCRIPTION DRUG LABEL 1 43063-248 CAPSULE 5 mg ORAL ANDA 22 sections